Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Semma's Series B brings in $114mm

Executive Summary

Three-year-old regenerative medicine firm Semma Therapeutics Inc. raised $114mm in an oversubscribed Series B financing co-led by Eight Roads Ventures and Cowen Healthcare Investments, which each add a board member and were joined by returning shareholders MPM Capital, F-Prime Capital Partners, Arch Venture Partners, Medtronic, and JDRF, partner Novartis, and first-time backers ORI Healthcare Fund, Wu Capital, 6 Dimensions Capital, and SinoPharm Capital. Semma will use the funds to move its encapsulated stem cell-derived islets program through clinical proof-of-concept for Type I diabetes.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies